Phase 1 Leukaemia Trial, Recruiting NCT05995041 Sponsor: Shenzhen Geno-Immune Medical Institute Condition: Leukaemia
Back to Leukaemia

Phase 1 Leukaemia Trial, Recruiting

NCT05995041
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are older than 6 months of age.
  • Your leukemia (AML) cells have been tested and confirmed to carry certain specific markers called CLL-1, CD123, CD38, and/or CD33, identified through a lab test on a tissue or blood sample.
  • You are generally in good health and able to carry out most daily activities, and doctors expect you to live for more than 3 months.
  • Your heart, liver, and kidneys are working well enough to meet specific lab test thresholds (confirm exact values with the trial site).
  • Your hemoglobin (a measure of red blood cells) is at an adequate level (at least 80 g/L).
  • You do not have any medical reasons that would prevent a cell separation procedure (a process used to collect certain blood cells).
  • You are able to understand the study and are willing to sign a consent form agreeing to take part.

Who may not be able to join:

  • You have a serious illness or medical condition, including an active infection that is not under control, that would make it unsafe to follow the study plan.
  • You have an active bacterial, fungal, or viral infection that has not been brought under control with treatment.
  • You have a known HIV infection or an active Hepatitis C infection.
  • You are currently pregnant or breastfeeding.
  • You have taken steroid medications (glucocorticoids) as a whole-body treatment within one week before joining the trial.
  • You have previously received any gene therapy treatment.
  • More than 50% of your bone marrow is made up of leukemia cells at the time of joining.
  • In the opinion of the study doctors, you may not be able to follow the study rules and requirements.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 0755-86573763

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Shenzhen Geno-Immune Medical Institute
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
31 December 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Safety of infusion

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov